Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

BACKGROUND: RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall surv...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Boxerman, Jerrold L., Zhang, Zheng, Safriel, Yair, Larvie, Mykol, Snyder, Bradley S., Jain, Rajan, Chi, T. Linda, Sorensen, A. Gregory, Gilbert, Mark R., Barboriak, Daniel P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3688018/
https://ncbi.nlm.nih.gov/pubmed/23788270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not049
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller